Evidence map›Paper›PMID 15767666›Full record

ArticleMolecular and cellular biology2005

Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.

Saskia M Brachmann, Claudine M Yballe, Metello Innocenti, Jonathan A Deane, David A Fruman, Sheila M Thomas, Lewis C Cantley

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 126 citations in OpenAlex.

  1. Article
  2. Article
  3. Therapeutic Role of Synthetic Lethality inJournal of immunotherapy and precision oncology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Dysregulated actin dynamics in activated PI3Kδ syndrome.Clinical immunology (Orlando, Fla.) · 2020
    Article
  11. Article
  12. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Saskia M BrachmannBeth Israel Hospital, NRB, Division of Signal Transduction, Department of Systems Biology,10th Floor, 330 Brookline, MA 02215, USA.
Claudine M Yballe
Metello Innocenti
Jonathan A Deane
David A Fruman
Sheila M Thomas
Lewis C Cantley
University of California, Irvine · USBeth Israel Deaconess Hospital · USBeth Israel Deaconess Medical Center · USEuropean Institute of Oncology · IT

Funding

Transgenic Mouse CoreP01CA089021 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SELLERS, WILLIAM R · 2001 to 2011
$20.1M
The Role of PI3K in Growth RegulationR01GM041890 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CANTLEY, LEWIS C. · 1990 to 2016
$4.1M
PHOSPHATDYLINOSITOL-3-P AND GROWTH REGULATIONR37GM041890 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CANTLEY, LEWIS C. · 1999 to 2008
$3.8M
Phosphoinositide 3-Kinase Function in LymphocytesR01AI050831 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FRUMAN, DAVID A · 2002 to 2006
$1.6M
SIGNALING THROUGH THE CYTOSKELETAL PROTEIN, PAXILLINR01CA075621 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI THOMAS, SHEILA M · 1997 to 2001
$520k
NCI NIH HHS CA75621NCI NIH HHS P01 CA089021NCI NIH HHS P01-CA089021NIAID NIH HHS AI50831NIAID NIH HHS R01 AI050831NIGMS NIH HHS GM41890NIGMS NIH HHS R01 GM041890NIGMS NIH HHS R37 GM041890
6 · The paper itself

Abstract

Class Ia phosphoinositide 3-kinases (PI3Ks) are heterodimers of p110 catalytic and p85 regulatory subunits that mediate a variety of cellular responses to growth and differentiation factors. Although embryonic development is not impaired in mice lacking all isoforms of the p85alpha gene (p85alpha-/- p55alpha-/- p50alpha-/-) or in mice lacking the p85beta gene (p85beta-/-) (D. A. Fruman, F. Mauvais-Jarvis, D. A. Pollard, C. M. Yballe, D. Brazil, R. T. Bronson, C. R. Kahn, and L. C. Cantley, Nat Genet. 26:379-382, 2000; K. Ueki, C. M. Yballe, S. M. Brachmann, D. Vicent, J. M. Watt, C. R. Kahn, and L. C. Cantley, Proc. Natl. Acad. Sci. USA 99:419-424, 2002), we show here that loss of both genes results in lethality at embryonic day 12.5 (E12.5). The phenotypes of these embryos, including subepidermal blebs flanking the neural tube at E8 and bleeding into the blebs during the turning process, are similar to defects observed in platelet-derived growth factor receptor alpha null (PDGFRalpha-/-) mice (P. Soriano, Development 124:2691-2700, 1997), suggesting that PI3K is an essential mediator of PDGFRalpha signaling at this developmental stage. p85alpha-/- p55alpha+/+ p50alpha+/+ p85beta-/- mice had similar but less severe defects, indicating that p85alpha and p85beta have a critical and redundant function in development. Mouse embryo fibroblasts deficient in all p85alpha and p85beta gene products (p85alpha-/- p55alpha-/- p50alpha-/- p85beta-/-) are defective in PDGF-induced membrane ruffling. Overexpression of the Rac-specific GDP-GTP exchange factor Vav2 or reintroduction of p85alpha or p85beta rescues the membrane ruffling defect. Surprisingly, reintroduction of p50alpha also restored PDGF-dependent membrane ruffling. These results indicate that class Ia PI3K is critical for PDGF-dependent actin rearrangement but that the SH3 domain and the Rho/Rac/Cdc42-interacting domain of p85, which lacks p50alpha, are not required for this response.

Indexed as

ActinsAnimalsCell MembraneCell Surface ExtensionsEmbryo LossEmbryo, MammalianExtracellular Signal-Regulated MAP KinasesIsoenzymesMiceMice, KnockoutMolecular WeightPhosphatidylinositol 3-KinasesPhosphorylationPlatelet-Derived Growth FactorProtein Serine-Threonine KinasesProto-Oncogene ProteinsActinsExtracellular Signal-Regulated MAP KinasesIsoenzymesPhosphatidylinositol 3-KinasesPlatelet-Derived Growth FactorProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-akt

Identifiers

PMID15767666
PMCPMC1061637
OpenAlexW1981682252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.